[go: up one dir, main page]

MX2018005399A - Nuevo polipeptido con afinidad por pd-l1. - Google Patents

Nuevo polipeptido con afinidad por pd-l1.

Info

Publication number
MX2018005399A
MX2018005399A MX2018005399A MX2018005399A MX2018005399A MX 2018005399 A MX2018005399 A MX 2018005399A MX 2018005399 A MX2018005399 A MX 2018005399A MX 2018005399 A MX2018005399 A MX 2018005399A MX 2018005399 A MX2018005399 A MX 2018005399A
Authority
MX
Mexico
Prior art keywords
affinity
new polypeptide
present disclosure
binding polypeptide
relates
Prior art date
Application number
MX2018005399A
Other languages
English (en)
Other versions
MX382321B (es
Inventor
Wahlberg Elisabet
Gunneriusson Elin
Original Assignee
Affibody Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody Ab filed Critical Affibody Ab
Publication of MX2018005399A publication Critical patent/MX2018005399A/es
Publication of MX382321B publication Critical patent/MX382321B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se refiere a una clase de polipéptidos modificados que tienen una afinidad de unión por el ligando de muerte programada 1 (``PD-L1´´, por sus siglas en inglés), y proporciona un polipéptido de unión a PD-L1 que comprende la secuencia ERNX4AAX7EIL X11LPNLX16X17X18QX20 WAFIWX26LX28D. La presente descripción también se refiere al uso de dicho polipéptido de unión a PD-L1 como un agente terapéutico, de pronóstico y/o de diagnóstico.
MX2018005399A 2015-10-30 2016-10-28 Nuevo polipéptido con afinidad por pd-l1. MX382321B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15192364 2015-10-30
EP16157154 2016-02-24
PCT/EP2016/076040 WO2017072280A1 (en) 2015-10-30 2016-10-28 New polypeptide having affinity to pd-l1

Publications (2)

Publication Number Publication Date
MX2018005399A true MX2018005399A (es) 2018-06-06
MX382321B MX382321B (es) 2025-03-13

Family

ID=57223674

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005399A MX382321B (es) 2015-10-30 2016-10-28 Nuevo polipéptido con afinidad por pd-l1.

Country Status (14)

Country Link
US (1) US11155596B2 (es)
EP (2) EP3693378A1 (es)
JP (1) JP6810143B2 (es)
KR (1) KR102805258B1 (es)
CN (1) CN108290931A (es)
AU (1) AU2016347495B2 (es)
CA (1) CA3001264A1 (es)
ES (1) ES2773504T3 (es)
IL (1) IL258419B (es)
MX (1) MX382321B (es)
MY (1) MY187827A (es)
RU (1) RU2749110C2 (es)
WO (1) WO2017072280A1 (es)
ZA (1) ZA201802542B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX385081B (es) 2014-11-25 2025-03-14 Bristol Myers Squibb Co Métodos y composiciones para radioetiquetado con 18f de productos biológicos.
AU2015353573B2 (en) 2014-11-25 2020-09-03 Bristol-Myers Squibb Company Novel PD-L1 binding polypeptides for imaging
MX2017011644A (es) 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
JP6990652B2 (ja) 2015-10-30 2022-02-03 アフィボディ・アーベー 新規ポリペプチド
EP3463486A1 (en) * 2016-06-01 2019-04-10 Bristol-Myers Squibb Company Pet imaging with pd-l1 binding polypeptides
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
JP2021514649A (ja) 2018-03-01 2021-06-17 ブレイエ・ユニバージテイト・ブリュッセルＶｒｉｊｅ Ｕｎｉｖｅｒｓｉｔｅｉｔ Ｂｒｕｓｓｅｌ ヒトｐｄ−ｌ１結合免疫グロブリン
IT201800003470A1 (it) * 2018-03-13 2019-09-13 Biotecnomed Soc Consortile A Resp Limitata Peptide and uses thereof
CN110054666B (zh) * 2019-03-12 2021-01-01 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种用于抑制细胞pd-l1表达的多肽及其应用
WO2021089695A1 (en) 2019-11-05 2021-05-14 Affibody Ab Polypeptides
EP3878858A1 (en) * 2020-03-11 2021-09-15 Affilogic Variants of sac7d and their use in cancer therapy
JP2024504136A (ja) * 2021-01-19 2024-01-30 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ 「新規な二環式ペプチド」
EP4476247A1 (en) 2022-02-08 2024-12-18 Affibody AB Protein z variants binding thymic stromal lymphopoietin and their medical use
CN119677787A (zh) 2022-08-10 2025-03-21 兴和株式会社 亲和体微胞药物复合体
KR20250140097A (ko) 2023-01-30 2025-09-24 키맵 리미티드 항체
CN121038816A (zh) 2023-05-04 2025-11-28 阿菲博迪公司 新多肽
GB202318675D0 (en) 2023-12-06 2024-01-17 Oncopeptides Ab Novel polypeptides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
WO2009089149A1 (en) * 2008-01-03 2009-07-16 The Johns Hopkins University B7-h1 (cd274) antagonists induce apoptosis of tumor cells
CN104768976B (zh) * 2012-10-05 2020-09-22 阿菲博迪公司 Her3结合多肽
EP2935335B1 (en) 2012-12-19 2020-10-28 Affibody AB New polypeptides
MX366425B (es) * 2013-03-15 2019-07-04 Affibody Ab Nuevos polipeptidos.
CN103304638B (zh) 2013-07-08 2014-12-03 郑州大学 具有抗肿瘤活性的pd-l1亲和肽及其应用
SG11201604956SA (en) * 2013-12-17 2016-07-28 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
CN103936835B (zh) 2014-04-29 2016-03-30 郑州大学 具有抗肿瘤活性的靶向PD-L1IgV亲和肽D1
CN104086627B (zh) * 2014-05-29 2016-06-08 郑州大学 具有抗肿瘤活性的PD-L1 IgV亲和肽S10
CN104761633B (zh) * 2015-03-25 2018-11-27 新乡学院 阻断猪pd-1/pd-l1通路的多肽及其应用
JP6990652B2 (ja) 2015-10-30 2022-02-03 アフィボディ・アーベー 新規ポリペプチド

Also Published As

Publication number Publication date
NZ741586A (en) 2021-11-26
CA3001264A1 (en) 2017-05-04
KR102805258B1 (ko) 2025-05-12
BR112018007154A2 (pt) 2018-11-06
JP6810143B2 (ja) 2021-01-06
US20180312565A1 (en) 2018-11-01
EP3368545B1 (en) 2019-12-04
CN108290931A (zh) 2018-07-17
RU2018117862A3 (es) 2020-03-02
EP3693378A1 (en) 2020-08-12
AU2016347495A1 (en) 2018-05-10
ZA201802542B (en) 2020-08-26
EP3368545A1 (en) 2018-09-05
HK1255250A1 (en) 2019-08-09
US11155596B2 (en) 2021-10-26
IL258419A (en) 2018-06-28
MY187827A (en) 2021-10-26
IL258419B (en) 2021-10-31
JP2018537965A (ja) 2018-12-27
RU2018117862A (ru) 2019-12-02
KR20180072797A (ko) 2018-06-29
RU2749110C2 (ru) 2021-06-04
ES2773504T3 (es) 2020-07-13
AU2016347495B2 (en) 2020-07-02
WO2017072280A1 (en) 2017-05-04
MX382321B (es) 2025-03-13

Similar Documents

Publication Publication Date Title
MX2018005399A (es) Nuevo polipeptido con afinidad por pd-l1.
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
EP3957723A3 (en) Engineered ligase variants
PH12018502400A1 (en) Anti-tim-3 antibodies and methods of use thereof
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
MY191944A (en) Binding proteins and methods of use thereof
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
MY198059A (en) Anti-ox40 antibodies and their uses
SG10201909716RA (en) Modified j-chain
MY188784A (en) Il-17a-binding polypeptides
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MY187971A (en) Antibody constructs for cd70 and cd3
MY191581A (en) Anti-pd-1 antibodies
MX2018003689A (es) Proteinas de union a pd-1 y metodos para usarlas.
SG10201803042PA (en) Anti-tim-3 antibodies
PH12022551462A1 (en) Ilt3-binding agents and methods of use thereof
SG10201902326XA (en) Mk2 inhibitors and uses thereof
BR112016029318A2 (pt) tratamento de mielomas
MX2020002435A (es) Agentes que modulan las funciones de beta-catenina y sus métodos.
PH12019502694A1 (en) Anti-trkb antibodies
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
PH12015501854A1 (en) Factor ix polypeptide formulations
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
WO2018189661A3 (en) Methods and compounds for treating diabetes